Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

1 year ago CAR-T

Approval of #Liver Cancer CAR-T Product Targeting #GPC3 Propels China’s CAR-T Therapy Forward

Liver cancer, CAR-T

CT011

On January 15, 2024, #CARsgen Pharmaceuticals announced that its autologous #CARTcell candidate product #CT011, targeting Glypican-3 (GPC3), has been approved for clinical use in China. It is intended for the treatment of GPC3-positive stage IIIa hepatocellular carcinoma patients at risk of recurrence after surgical resection.

Glypican-3 (GPC3)

Glypican-3 (GPC3)plays a crucial role in regulating cell growth and differentiation and is closely associated with the occurrence and progression of liver cancer. GPC3 is expressed in reproductive system tumors such as hepatocellular carcinoma, ovarian clear cell carcinoma, and yolk sac tumors. Its expression rate in hepatocellular carcinoma reaches 74.8%, while it is virtually absent in normal liver tissue, making it an ideal new target for #livercancer #CARTtherapy.

Promising Target

Due to its tumor specificity, GPC3 is considered a promising target for cancer immunotherapy. Higher expression of GPC3 in hepatocellular carcinoma is associated with poorer prognosis.

Frontiers in Immunology

In August 2022, a Chinese medical team published a long-term survival case report of treating advanced hepatocellular carcinoma with CT011 in the journal “#FrontiersinImmunology.” The study reported complete remission (#CR) and long-term survival in a patient with advanced hepatocellular carcinoma after receiving GPC3 CAR-T cell therapy in combination with the multi-target kinase inhibitor sorafenib.

Results showed good tolerance to CT011 combined with sorafenib treatment. The patient achieved partial remission (PR) from the third month onwards and attained complete remission at the 12th month after the first CT011 infusion. The tumor did not progress for over 36 months, maintaining complete remission status for over 24 months after the first infusion.

Cancer Communications

On October 12, 2023, CARsgen Pharmaceuticals announced the clinical efficacy of its independently developed CAR-T cell therapy targeting GPC3 in two patients with advanced hepatocellular carcinoma (HCC). The clinical trial results were published in “#CancerCommunications.” Both patients had inferior prognostic outcomes upon enrollment, with one having inferior vena cava tumor thrombus and the other having retroperitoneal lymph node metastasis.

In the clinical trial, one patient received local treatment for intrahepatic recurrent tumors and inferior vena cava tumor thrombus (microwave ablation and gamma knife) before receiving CAR-T cell therapy targeting GPC3. Six months later, AFP (alpha-fetoprotein) levels normalized, and imaging revealed no active tumors. The other patient underwent local treatment (microwave ablation and gamma knife) for controlling intrahepatic tumors, inferior vena cava tumor thrombus, and peritoneal lymph node metastases while receiving CAR-T cell therapy.

Encouragingly, both patients showed significant efficacy after combined local treatment and CAR-T cell infusion, maintaining tumor-free status during long-term follow-up, with both individuals being tumor-free for over 7 years. Throughout the follow-up period, both patients only received oral antiviral therapy for hepatitis B and did not undergo any other cancer treatment.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#CART #Immunotherapy #LiverCancer #CancerResearch #MedicalInnovation #Healthcare #ClinicalTrials #SurvivorStories #GPC3 #PrecisionMedicine

1 year ago patient story , Myeloma

🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈

cancer fight

🌟Mr. C from California, USA

It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.

🌞New treatment method

Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.

🌤Upon arriving in China,

Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.

🔥Hope and Courage

Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.

☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!

⭐️CAR-T therapy

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070

✨The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

1 year ago Myeloma

$160,000 per dose! The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

🌈 $160,000 per dose! 🌈

⭐The first approved CAR-T therapy in China, Zevor-cel by CARsgen, announces its initial price for the treatment of multiple myeloma.

multiple myeloma

Zevor-cel

🌦On March 5th, the fifth approved CAR-T therapy in China, Zevor-cel injection (Zevor-cel) by CARsgen, was priced at $116,000 for its initial release.

Zevor-cel injection is an autologous CAR-T product targeting BCMA. It is the fifth CAR-T therapy approved and marketed in China, following Axicabtagene Ciloleucel by Fosun Kite, Relmacabtagene Autoleucel by JW Therapeutics, Equecabtagene Autoleucel by IASO Bio, and Inaticabtagene Autoleucel by Juventas.

Cheapest CAR-T therapy

🌺Currently, the cheapest approved CAR-T therapy in the world is Inaticabtagene Autoleucel by Juventas. The price has dropped below one million RMB, at 999,000 RMB (equivalent to less than $140,000).

US CAR-T

🌼In 2017, the US FDA approved two CAR-T products, marking the beginning of the era of immunocellular therapy. CAR-T therapy has always been known for its high prices. Just how expensive is it? The two CAR-T therapies approved for sale in the United States are priced at $475,000 (Kymriah) and $373,000 (Yescarta), and these are just the prices of the drugs themselves. The total cost of the treatment far exceeds these amounts.

Multiple Myeloma

🌻For the treatment of multiple myeloma, there are currently two CAR-T products on the US market: Idecabtagene vicleucel by BMS/bluebird bio and ciltacabtagene autoleucel by Legend Bio. They are priced at $419,000 and $465,000, respectively, with a BCMA target and a complete response (CR) rate of 28% and 78%.

In China

⚡ there are also two CAR-T products on the market: Zevor-cel injection by CARsgen and Equecabtagene Autoleucel injection by IASO Bio. They are priced at $160,000 and $162,000, respectively, with the same BCMA target and CR rates as high as 78.6% and 82.4%.

🌤To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp+8613717959070

doctor.huang@globecancer.com

#CARTtherapy #CancerTreatment #Immunotherapy #MultipleMyeloma #BCMA #Zevorcel #CARsgen #MedicalBreakthrough #HealthcareInnovation #PrecisionMedicine #PersonalizedMedicine #MedicalAdvancements #FightAgainstCancer #GlobalHealthcare #AffordableMedicine

#CancerResearch #PatientCare #MedicalTechnology #InnovativeTherapy #HopeForPatients

1 year ago CAR-T

Putin Says Russia Is Close to Creating Cancer Vaccines. A Look at China’s Advancements

Putin

Recently, a viral piece of information has swept the internet. According to reports, Russian President Putin revealed that Russian scientists are close to developing a cancer vaccine and a new generation of immunomodulatory drugs, which can soon be made available to patients for effective personalized treatment.

However, Putin did not specify which type of cancer this vaccine would prevent or how it would prevent it. Nevertheless, this news has spread widely internationally, with some even exaggerating its effectiveness. So, is this really true?

It is reported that the information revealed by President Putin is indeed true and will soon be used for personalized treatment. It can be confirmed that this cancer vaccine is a therapeutic vaccine. However, it is not a treatment for all types of cancer but rather a “highly customized” vaccine based on a certain gene sequencing, targeting different mutation sites, including multiple sites, for each patient.

Cancer vaccines are a form of active immunotherapy and an important part of tumor immunotherapy. They work by stimulating or restoring the body’s own immune system to prevent cancer development or kill existing tumors. Cancer vaccines mainly include cell vaccines, DNA vaccines, mRNA vaccines, peptide vaccines, dendritic cell vaccines, nano vaccines, etc., and have shown promising clinical efficacy in the treatment of solid tumors such as malignant melanoma, lung cancer, ovarian cancer, and cervical cancer.

Cancer Vaccines

According to data from clinicaltrials.gov, China has about 150 ongoing tumor vaccine projects. China’s first mRNA tumor vaccine is targeting FDA approval, and more tumor mRNA vaccines are emerging, targeting lung cancer, pancreatic cancer, breast cancer, and more.

The personalized tumor neoantigen vaccine LK101 injection has been approved for clinical use!

On March 15, 2023, according to the official website of the National Medical Products Administration Drug Evaluation Center (CDE), the new drug clinical trial application (IND) of the personalized tumor neoantigen vaccine “LK101 injection” independently developed by Beijing Likang Life was approved for the treatment of advanced solid tumors.

It is reported that this product is the first domestically approved personalized tumor neoantigen vaccine to enter clinical stage and the first completely personalized mRNA editing product approved for clinical stage in China, marking a milestone event in the field of mRNA tumor vaccines in China.

On December 22, 2022, LK101 injection submitted a new drug clinical research application (IND) and was accepted. This personalized tumor neoantigen vaccine adopts the form of mRNA-DC (mRNA-dendritic cell) vaccine, which transfects dendritic cells with mRNA encoding tumor neoantigens ex vivo. The vaccine not only has high safety and good tolerance but also can provide patients with long-term anticancer effects.

Disease iNeo-Vac-P01 new antigen vaccine!

Personalized cancer vaccines significantly effective against a wide range of advanced solid tumors

The research team of Zhejiang Shao Yifu Hospital designed a peptide-based neoantigen vaccine iNeo-Vac-P01 and conducted a prospective clinical trial, enrolling a total of 22 patients with standard treatment failure and a wide range of advanced solid tumors. Using the iNeo artificial intelligence vaccine design platform, personalized peptide drug preparation and quality control system were used to customize iNeo-Vac-P01 vaccine for each patient.

After treatment, the results showed that among the 22 patients with advanced malignant tumors, 20 had no adverse reactions or had mild adverse reactions. The disease control rate was 71.4%, and the median progression-free survival was 4.6 months, with the median survival not yet reached.

The study suggests that for patients with advanced solid tumors, iNeo-Vac-P01 monotherapy is feasible and safe. It can induce T-cell-mediated immune responses against tumor neoantigens and may have good anti-tumor efficacy.

JCXH-211: Targeting multiple solid tumors with tumor neoantigen mRNA vaccine

Recently, a tumor neoantigen mRNA vaccine developed by Jiachen Xihai Biotechnology Co., Ltd. JCXH-211 has obtained FDA’s IND approval. JCXH-211 is a novel drug based on self-replicating mRNA encoding interleukin-12 (IL-12), which can express IL-12 in the body at a low dose for a long time and is suitable for the potential treatment of various advanced solid tumors.

Preclinical studies have shown that JCXH-211 can effectively kill tumor cells, eliminate distant tumors, and prevent tumor recurrence. This excellent tumor clearance effect is due to the strong antiviral immune response induced by RNA replicons and the strong antitumor immune response activated by IL-12. In comprehensive GLP toxicological studies, JCXH-211 has shown high safety.

The Phase 1 clinical trial of JCXH-211 will evaluate the efficacy of single-agent JCXH-211 in patients with advanced malignant solid tumors who have progressed or cannot tolerate existing treatments after receiving current treatment. This trial is open to patients aged 18 or older with at least one tumor lesion suitable for IT injection, measurable disease according to RECIST1.1, sufficient organ function, and an ECOG physical status of 0 to 1. Let’s wait and see its effectiveness!

#JCXH211 #cancer #CancerVaccine #ImmunotherapyBreakthrough #PersonalizedTreatment #TumorVaccine #mRNAVaccine #NeoantigenVaccine #CancerResearch #PrecisionMedicine #ClinicalTrials #MedicalInnovation

1 year ago CAR-T

TIL Therapy: Revolutionizing Cancer Treatment Worldwide! China Accelerates into the Fast Lane!

🌟 TIL Therapy: Revolutionizing Cancer Treatment Worldwide! 🌎 China Accelerates into the Fast Lane!

📈 The number of cell immunotherapy trials for solid tumor treatment has surged globally, with a staggering growth from 66 in 2020 to 140 in 2022, a remarkable 110% increase! Particularly, TIL therapy trials have seen a remarkable surge, now accounting for 17.1% of all solid tumor treatments, sparking a new trend in cancer therapy that’s capturing the attention of researchers and companies alike.

🎯 TIL therapy boasts natural advantages in solid tumor treatment, boasting rich tumor-specific target points, robust tumor infiltration capabilities, and minimal side effects.

🔬 On February 16, 2024, the U.S. FDA officially greenlights Iovance Biotherapeutics’ lifileucel therapy for unresectable or metastatic melanoma, a groundbreaking personalized T-cell therapy using TIL sourced from the patient’s body.

FDA

🚀 In early 2022, China’s Grit Biotechnology’s GT101 injection became the first TIL product to enter clinical trials, signaling China’s entry into the global TIL therapy scene. With players like Juncell Therapeutics, LANMA BIO, and BT Gillion joining the fray, Chinese TIL therapy is on the fast track to development, exploring various indications including melanoma, cervical cancer, lung cancer, and more!

TIL therapy

💰 According to Sullivan’s forecast, the global CGT market is set to skyrocket to $22 billion by 2025, with TIL therapy leading the charge.

💡 Chinese TIL therapy is paving its own path to commercialization and industrialization, offering cost-effective treatments compared to the U.S. Stay tuned for more innovations in cancer therapy from China! 🇨🇳

🌟We have access to medical resources from all cancer hospitals in China and can assist patients in receiving treatment from the best and top-tier oncologists in the CHINA.

doctor.huang@globecancer.com

WhatsApp+8613717959070

#TILTherapy #CancerTreatment #Innovation #MedicalBreakthroughs #ChinaHealthcare #GlobalHealthcare #CancerResearch 🚀🔬

1 year ago CAR-T

Hope For Patients of Gastric Cancer And Pancreatic Cancer – CT041 Typical Cases and Achievements

🔬✨Hope For Patients of Gastric And Pancreatic Cancer – CT041 Typical Cases and Achievements ✨🔬

Patient 1: 53-year-old Male

Gastric Cancer,
Pancreatic Cancer

Advanced gastric cancer with liver, lung, bone metastases, and multiple lymph nodes and peritoneal metastases. Previously treated with 2 systemic therapies including PD-1 antibodies, CLDN18.2 expression 60% (3+). After CAR-T therapy, tumor size decreased by nearly 50%, achieving sustained remission for 32 weeks.

Patient 2: 57-year-old Female

Gastric Cancer,
Pancreatic Cancer

Gastric cancer with peritoneal metastasis and Sister Mary Joseph’s nodule (malignant tumor metastasis forming a nodule-like lesion in the umbilicus). Previously received third-line therapy including PD-1 antibodies, CLDN18.2 expression 80% (2+). Achieved partial remission after CAR-T therapy, with sustained response exceeding 56 weeks.

🏆 CT041 Achievements 🏆

– In May 2020, FDA approved CT041 for investigational new drug (IND) authorization for the treatment of claudin18.2-positive gastric, gastroesophageal junction, or pancreatic adenocarcinoma patients.

– In 2020, received orphan drug designation from the U.S. FDA for the treatment of gastric/gastroesophageal junction cancer.

– In 2021, granted orphan drug designation by the European Medicines Agency (EMA) and qualified for the European PRIME program.

– In 2022, received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA.

– On March 3, 2022, approved by the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) to enter Phase II clinical trials!

We are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address:

doctor.huang@globecancer.com,

or WhatsApp+8613717959070

The Medical Department will contact you as soon as they receive the reports.

#CancerResearch #Immunotherapy #CART #MedicalBreakthrough #ClinicalTrials #FDAApproval #OrphanDrug #HealthcareInnovation #GastricCancer #PancreaticCancer #CT041 #MedicalAdvancement #RegenerativeMedicine #RMAT #EMAApproval #NMPAApproval #MedicalScience #PrecisionMedicine #PatientCare

1 year ago CAR-T

Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results!

🎉 Breaking News: Another Milestone for Domestic CAR-T Therapy! Clinical Benefit Rate Reaches 71.4% in CT041 Trials, Challenging Gastric and Pancreatic Cancers with Astonishing Results! 🚀

Gastric Cancer， Pancreatic Cancer

A burgeoning therapeutic target for gastric cancer—Claudin 18.2, its discovery has also opened a new chapter in targeted therapy for gastric cancer. If we talk about the hottest cell immunotherapy in recent years, it has to be chimeric antigen receptor T-cell (CAR-T) therapy. Based on this, Chinese researchers have developed the world’s first CAR-T cell therapy targeting Claudin18.2—CT041.

CT041, as the first CAR-T cell therapy targeting Claudin18.2, made its debut at the 2019 ASCO Annual Meeting. Among 12 patients with metastatic adenocarcinoma (7 gastric cancer, 5 pancreatic cancer) treated with Claudin18.2-targeting CAR T-cell therapy, no severe adverse events, treatment-related deaths, or serious neurotoxicity were reported. Among the 11 evaluated patients: 1 (gastric adenocarcinoma) achieved complete remission; 3 (2 gastric adenocarcinoma, 1 pancreatic adenocarcinoma) achieved partial remission; 5 had stable disease; and 2 experienced disease progression. The overall objective response rate was 33.3%.

At the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) held on January 19, 2024, SciGen showcased a clinical study of Claudin18.2-targeting autologous CAR-T cell therapy CT041 (satri-cel), reporting results from the dose escalation phase of the ELIMYN18.2 1b clinical trial conducted in the United States for the treatment of gastric/esophagogastric junction adenocarcinoma (GC/GEJ) or pancreatic cancer (PC).

This single-arm, open-label phase 1b/2 study primarily evaluated the safety and efficacy of CT041 in patients with advanced Claudin18.2-positive gastric/esophagogastric junction adenocarcinoma (GC/GEJ, progressing after at least second-line treatment or intolerant) or pancreatic cancer (PC, progressing after at least first-line treatment or intolerant).

Nineteen patients (9 GC/GEJ patients, 12 PC patients) received CT041 treatment at doses ranging from 250 to 600×106 cells: dose 1: 250-300×106 (n=6), dose 2: 375-400×106 (n=6), dose 3: 600×106 (n=7). All patients had received systemic therapy, with 85.7% of GC/GEJ patients and 58.3% of PC patients receiving ≥3 lines of systemic therapy. The median number of metastatic organs for all patients was 2, with at least one prior infusion. Clinical benefit rate included complete remission [CR], partial remission [PR], and stable disease [SD] ≥180 days.

As of September 15, 2023, with a median follow-up of 8.9 months, across all dose groups, the confirmed objective response rate (ORR) for gastric/esophagogastric junction adenocarcinoma patients was 42.9% (3/7); clinical benefit rate (CBR) was 57.1% (4/7); median progression-free survival (mPFS) and median duration of response (mDOR) were 5.7 months and 6.9 months, respectively. Additionally, the median overall survival (mOS) for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 8.9 months. In dose level 3 (DL3), one gastric/esophagogastric junction adenocarcinoma patient achieved complete remission (CR). The clinical benefit rate for gastric/esophagogastric junction adenocarcinoma or pancreatic cancer patients was 71.4% (5/7), with a median OS of 12.9 months.

In summary, #CT041, as the first autologous #Claudin182 CAR-T cell therapy, demonstrates encouraging safety and shows promising preliminary efficacy in Claudin18.2-positive advanced GC/GEJ and PC patients who have received multiple prior treatments.

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the email address: doctor.huang@globecancer.com, or click on the WhatsApp+8613717959070 icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

🌟 #CART #Immunotherapy #CT041 #CancerResearch #ClinicalTrials #GastricCancer #PancreaticCancer #SciGen #ASCOGI2024

1 year ago CAR-T

Haematologica Spotlight：A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

🔬 Haematologica Spotlight 🔬

A Chinese team published the largest-scale pediatric-style regimen treatment for adult Ph-negative ALL

Acute Lymphoblastic Leukemia (ALL)

is a hematological malignancy characterized by the proliferation of immature lymphoid cells in the bone marrow, peripheral blood, and extramedullary sites. While the prognosis for childhood ALL is relatively favorable, with a 5-year overall survival rate of 80-90%, adult ALL poses greater challenges. Approximately 20-30% of adult acute leukemias are ALL, with about two-thirds being Philadelphia chromosome-negative (Ph-negative) ALL. Conventional adult ALL treatments have shown high remission rates but also high relapse rates and poor long-term survival.

Haematologica

Inspired by the success of pediatric ALL treatments, especially in adolescent and young adult patients, the Hematology Center at the

Chinese Academy of Medical Sciences and Peking Union Medical College Hospital

embarked on a groundbreaking journey. Their pioneering research, recently published in *Haematologica*, presents the results of the largest prospective cohort study in China investigating the efficacy of a pediatric-inspired regimen in adult Ph-negative ALL patients.

The study, led by Dr. Wang Jianxiang and his team,

evaluated the IH-2014 regimen’s effectiveness in 415 newly diagnosed adult Ph-negative ALL patients treated between April 2014 and December 2021, with a median age of 27 years (range 14-65 years) and a median follow-up of 40.8 months. The overall 5-year overall survival (OS) and disease-free survival (DFS) rates were 53.8% and 51.1%, respectively, with a chemotherapy-related mortality rate of 3.6%.

Patients achieving complete remission (CR)

after induction therapy with available bone marrow minimal residual disease (MRD) data were categorized based on diagnostic risk: standard-risk (SR) MRD-negative (<0.01%) in 73 patients (18.8%), SR MRD-positive (≥0.01%) in 69 patients (17.7%), high-risk (HR) MRD-negative in 120 patients (30.8%), and HR MRD-positive in 127 patients (32.6%). The 5-year OS rates for these groups were 82.6%, 58.7%, 58.3%, and 36.1%, respectively (P＜0.001), with corresponding cumulative relapse rates of 24.2%, 41.1%, 36.3%, and 50.1% (P＜0.001). Multivariate analysis identified age ≥40 years and MRD positivity after induction as independent adverse prognostic factors for OS and DFS.

In conclusion, the IH-2014 regimen demonstrates significant efficacy and good tolerability in adult Ph-negative ALL patients, with younger patients (<40 years) benefiting more prominently. Induction treatment response combined with MRD levels serves as a valuable prognostic indicator for long-term survival and relapse, guiding allogeneic hematopoietic stem cell transplantation decisions in patients achieving first complete remission (CR1).

This study marks a pivotal milestone in advancing adult ALL treatment strategies, showcasing China’s remarkable progress in the field of hematology. Stay tuned for more groundbreaking research from our team!

🎉To assess whether the condition is suitable for CAR-T therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: +8613717959070

🌟 #Haematologica #LeukemiaTreatment #PediatricInspiration #ALL #AcuteLymphoblasticLeukemia #LymphoblasticLeukemia #Leukemia

1 year ago CAR-T

Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma!

🌟 Exciting News Alert! China’s New TCR-T Product IND Approved for Synovial Sarcoma! 🌟

synovial sarcoma

“Engineered T Cell Receptor-T Cell Therapy,” or “TCR-T (engineered T cell receptor-T cell, TCR-T) cell therapy,” involves the extraction of peripheral blood mononuclear cell (PBMC) samples from patients, followed by genetic engineering to introduce selected high-affinity T cell receptors (TCRs) into T cells. This enables them to seek out and specifically recognize tumor antigens, effectively targeting and killing cancer cells.

In early 2022, the Food and Drug Administration (FDA) in the United States approved a TCR-T therapy called “Kimmtrack” for treating uveal melanoma, marking a significant milestone in solid tumor treatment.

Recently, the prestigious international journal “Cell Rep Med” reported the Phase I clinical trial results of China’s first investigational new drug (IND) approved by the FDA for TCR-T cell therapy — TAEST16001. This groundbreaking research represents a crucial step forward in the clinical translation of adoptive T cell immunotherapy for advanced soft tissue sarcoma and holds the potential to become the world’s second marketed TCR-T cell therapy targeting solid tumors!

Cell Rep Med

China’s first TCR-T product IND approval takes aim at synovial sarcoma.

TAEST16001,

developed independently by Xiangxue Life Sciences, is a TCR-T cell product. The Phase I clinical trial enrolled 12 patients with advanced soft tissue sarcomas who were HLA-A*02:01 positive and expressed the NY-ESO-1 antigen. Among them, 10 patients had synovial sarcoma, while 2 had liposarcoma (1 myxoid liposarcoma and 1 dedifferentiated liposarcoma), with a median age of 33 (25-67) years. 58.3% (7/12) of patients were male. Before enrollment, 83.3% of patients had received at least two types of chemotherapy. After enrollment, all patients underwent modified lymphocyte clearance surgery followed by infusion treatment with TAEST16001 cells.

After a median treatment duration of 43 days, 9 out of 12 patients (75%) showed tumor regression (Figure 1), with a median time to response (TTR) of 1.9 months and a median duration of response of 13.1 months. Six patients (50%) exhibited sustained tumor burden reduction after the first radiological assessment. In the primary analysis, 5 out of 12 patients achieved partial responses, resulting in an objective response rate (ORR) of 41.7% (95% CI, 15.2–72.3). Disease stabilization was observed in 5 cases [41.7% (95% CI, 15.2–72.3)], yielding a disease control rate of 83.3% (95% CI, 51.6–97.9). The median progression-free survival (PFS) was 7.2 months (95% CI, 2.5–11.8).

TCR-T Therapy

How to Seek TCR-T Therapy Assistance

Several TCR-T therapies under development in China are urgently recruiting patients with hepatitis B virus-related liver hepatocellular carcinoma, head and neck tumors (oral cancer, laryngeal cancer, etc.), advanced cervical cancer, and anal cancer.

If you wish to assess whether your condition is suitable for CAR-T therapy, you can submit your pathological reports, treatment history, and discharge summaries to

<Advanced Medicine in China> doctor.huang@globecancer.com for preliminary evaluation.

or click on the WhatsApp+8613717959070

Stay tuned for more updates on this groundbreaking advancement in cancer treatment! 🌟

#CancerResearch #TCRTtherapy #SynovialSarcoma #MedicalInnovation

1 year ago CAR-T

A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options!

🌟 A New Era in Lung Cancer Treatment – Serplulimab Brings Innovative and Reliable Therapeutic Options! 🌟

Cancer cell

📆CANCER CELL

January 5, 2023: The highly anticipated Phase 3 pivotal clinical trial (ASTRUM-004) of HANSIZHUANG, an anti-PD-1 monoclonal antibody developed independently by Henlius, in combination with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sqNSCLC), has just been published in the prestigious international oncology journal “Cancer Cell” (Impact Factor: 50.3)! Led by Professor Zhou Caicun from Shanghai Pulmonary Hospital, this milestone study signifies a significant breakthrough in lung cancer treatment.

🔬 Lung cancer

is one of the most common cancers globally, with the highest reported incidence and mortality rates in China. According to the latest statistics from the National Cancer Center, there are 828,000 new cases of lung cancer and 657,000 deaths annually. Non-small cell lung cancer (NSCLC) accounts for approximately 80% to 85% of all lung cancers, with a significant proportion diagnosed at an advanced stage or with metastasis, unsuitable for surgical resection.

🌱NSCLC

In the field of NSCLC treatment, immune checkpoint inhibitors have become a game-changer. Serplulimab is the first innovative monoclonal antibody developed independently by Henlius. Since its approval in March 2022, it has been approved in China for the treatment of microsatellite instability-high (MSI-H) solid tumors, sqNSCLC, extensive-stage small cell lung cancer (ES-SCLC), and esophageal squamous cell carcinoma (ESCC), benefiting over 51,000 patients.

🔍 ASTRUM-004

is a pivotal Phase 3 trial aimed at evaluating the efficacy and safety of serplulimab in combination with chemotherapy as first-line treatment for advanced sqNSCLC. The results are promising: patients receiving serplulimab demonstrated significantly prolonged progression-free survival (PFS) and overall survival (OS), with manageable safety profiles.

Serplulimab

🎉NEW ERA

These findings herald a new era in lung cancer treatment, offering a ray of hope for patients and clinicians alike. Serplulimab in combination with chemotherapy has emerged as a promising first-line treatment option, bringing innovation and reliability to sqNSCLC patients.

👩‍🔬Lead

Lead investigator Professor Zhou Caicun commented, “The ASTRUM-004 study validates the significant potential of serplulimab in combination with chemotherapy to improve survival outcomes in sqNSCLC patients, marking a major breakthrough in the field of lung cancer.”

🌟 Stay tuned for more updates as we continue to unravel the mysteries of cancer treatment, bringing hope to millions worldwide!

#CancerResearch #LungCancer #MedicalBreakthrough #InnovationForHealth #Serplulimab #NSCLC #ASTRUM #sqNSCLC #cancercell

1 year ago CAR-T

Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.

🌟 Chinese Hengrui Pharmaceuticals ‘s indication for cervical cancer has been approved for clinical trials.🌟

cervical cancer

🏥💊（Jiangsu Hengrui Pharmaceuticals Co., Ltd）Hengrui Pharmaceutical’s PD-L1 inhibitor Atezolizumab injection combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer has been approved for open, multicenter Phase II clinical trials.

Atezolizumab

🌸🎀#Cervical cancer is the fourth most common cancer in women globally, mainly caused by persistent infection with high-risk human papillomavirus (#HPV). Although the widespread implementation of #cervicalcancer screening and the availability of HPV vaccines have reduced the incidence of cervical cancer in developed countries, it remains one of the common malignant tumors in women.

🏥💊Atezolizumab injection is a humanized anti-PD-L1 monoclonal antibody independently developed by Hengrui Medicine. It is the first PD-L1 inhibitor approved for the treatment of small cell lung cancer in China. By specifically binding to the PD-L1 molecule, it blocks the PD-1/PD-L1 pathway that leads to tumor immune tolerance, reactivating the immune system’s anti-tumor activity and achieving the goal of tumor treatment.

The Lancet Oncology

🌸🎀Atezolizumab injection has been studied in various fields, including small cell lung cancer, #NSCLC non-small cell lung cancer, esophageal cancer, liver cancer, and cervical cancer. It has shown promising efficacy in small cell lung cancer. Based on the results of the SHR-1316-III-301 study, the application for the market approval of Atezolizumab injection combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer has been accepted and approved in China in March 2023. The study results have been published in the top international medical journal “The Lancet Oncology,” and the original research from China has been internationally recognized.

🏢💊Jiangsu Hengrui Pharmaceuticals Co., Ltd is committed to advancing the clinical research of the PD-L1 inhibitor Atezolizumab injection, bringing more innovative and effective treatment options for cervical cancer patients. Stay tuned for our progress!

Hengrui Pharmaceutical

🚑In addition to Cervical cancer, we are currently urgently recruiting patients with B-cell lymphoma, T-cell lymphoma, T-cell leukemia (T-ALL), acute lymphoblastic leukemia, myeloma, and other types of cancer!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to the 📩email address: doctor.huang@globecancer.com📩, or click on the ✉️WhatsApp+8613717959070✉️ icon on the homepage. The Medical Department will contact you as soon as they receive the reports.

#CervicalCancerTreatment #Atezolizumab #HengruiMedicine #ClinicalTrials #CancerTreatment #cervical #cervicalcancer #chinesemedicine #newdrug #Lancet #TheLancetOncology

📩References：　　

[1]gco.iarc.fr(WHO statistics)

　　[2]Rose PG,Bundy BN,Watkins EB,Thigpen JT,Deppe G,Maiman MA,Clarke-Pearson DL,Insalaco S:Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer.N Engl J Med1999,340(15):1144-1153.

　　[3]Pfaendler KS,Tewari KS:Changing paradigms in the systemic treatment of advanced cervical cancer.Am J Obstet Gynecol2016,214(1):22-30.

　　[4]Liu C,Lu J,Tian H,Du W,Zhao L,Feng J,Yuan D,Li Z:Increased expression of PDL1by the human papillomavirus16E7oncoprotein inhibits anticancer immunity.Mol Med Rep2017,15(3):1063-1070.

1 year ago CAR-T

Chinese Exciting Good News Update in Lung Cancer Treatment! ORR: 78.6%

Meet Sunvozertinib, the game-changer in advanced lung cancer therapy!

Sunvozertinib, NSCLC

This groundbreaking oral medication, a novel irreversible EGFR-TKI, targets multiple EGFR mutation subtypes with remarkable precision. What’s more? Sunvozertinib is now the FIRST and ONLY EGFR-TKI approved for treating late-stage NSCLC with EGFR exon20ins mutations!

At the 2023 ESMO Conference, fresh data from early trials of Sunvozertinib’s frontline treatment for EGFR exon20ins-mutated advanced NSCLC were unveiled, and the results were jaw-dropping!

With an astounding Objective Response Rate (ORR) of 78.6% and a median Progression-Free Survival (PFS) of 12.4 months at the recommended dose (300mg QD), Sunvozertinib once again set a new benchmark in this field, offering a superior treatment option for newly diagnosed patients with EGFR exon20ins mutations!

Let’s dive into a real success story: A 35-year-old male diagnosed with late-stage NSCLC harboring EGFR exon20ins mutations, along with metastases to the brain, liver, and bones. After showing stable disease (SD) following two cycles of platinum-based chemotherapy, he switched to Sunvozertinib. Just one month into treatment, a follow-up chest CT scan revealed a remarkable 34% reduction in the size of the left lower lobe lesion, with lung lesions shrinking from 29mm×26mm to 19mm×15mm (see image). Multiple nodules in the lungs and pleura also decreased in size, along with liver lesions. Evaluation: Partial Response (PR)!

Lung Cancer

Noteworthy is the impeccable safety profile of Sunvozertinib, with no significant adverse effects reported during treatment. As of this post, the patient continues to receive Sunvozertinib monotherapy with promising outcomes!

With breakthroughs in targeted therapies for EGFR exon20ins-mutated NSCLC, several new drugs are actively exploring frontline treatment options. The early study results of Sunvozertinib’s frontline therapy for EGFR exon20ins-mutated advanced NSCLC have once again rewritten the records in this field, providing new treatment guidelines for these patients!

#LungCancerAwareness #Sunvozertinib #EGFRexon20ins #NSCLC #TargetedTherapy #MedicalBreakthroughs #HealthcareInnovation #lungs #lung #lungcancer #chinesemedicine #EGFR

Menu

Tags Archives: Cancer Research